当前位置:循环首页>正文

ACCOMPLISH试验中CCB/ACEI联合方案由此带来的获益

Benefit of combination of CCB and ACEI in ACCOMPLISH

作者:  SverreErikKjeldsen   日期:2012/2/2 13:27:32

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

我认为氨氯地平当与ACEI或ARB联合应用时会表现更好。他们在降压效应和靶器官保护方面有互补作用,并且在耐受性方面相互平衡,不良反应更少(氨氯地平联合ACEI或ARB时,水肿的减少尤其明显)。

  作者简介:
  Sverre Erik Kjeldsen:挪威Ullevaal 大学医院心脏病学部教授,密歇根大学心血管医学部兼职教授。欧洲高血压学会(ESH)前主席(2005~2007)。曾获国际高血压学会奖、2008 Lennart Hansson纪念奖。
  我认为氨氯地平当与ACEI或ARB联合应用时会表现更好。他们在降压效应和靶器官保护方面有互补作用,并且在耐受性方面相互平衡,不良反应更少(氨氯地平联合ACEI或ARB时,水肿的减少尤其明显)。
  ACCOMPLISH试验显示CCB/ACEI联合方案较HCTZ/ACEI联合方案降低20%的硬终点事件发生率——这足以提前终止试验,并从根本上再次证实了ASCOT试验中CCB/ACEI vs. HCTZ/β受体阻滞剂对比的结果。ASCOT试验中CCB/ACEI组中血压更低,而我们在ACCOMPLISH试验中未观察到这种差异——所以,我们推断其获益独立于降压效应。氯噻酮有可能优于HCTZ。因此,美国JNC8指南在考虑以氯噻酮取代HCTZ作为一线治疗进行推荐。当然你可能主张在作出强烈推荐之前ACCOMPLISH还需要进一步确认——通常指南建议需要基于至少2项显示一致原则的研究。我仍然认为,ACEI/HCTZ 和 ARB/HCTZ是优秀的联合用药方案。
  I think, at this stage, BP variability is an interesting hypothesis, but one that needs further research to be proven. I would rather say that amlodipine behaves differently (better) when it acts in combination with an ACEI (or ARB). They are complementary regarding BP lowering effects and vessel/target organ protection and they balance each other regarding tolerability with less side effects (particularly less oedema from amlodipine when combined with an ACEI or ARB).
  ACCOMPLISH showed that CCB/ACEI combination is 20% better than HCTZ/ACEI combination in hard endpoint reduction - enough to stop the study early and essentially confirming what ASCOT suggested as far as CCB/ACEI vs. HCTZ/beta-blocker. In ASCOT there was somewhat lower BP for the CCB/ACEI. We did not see this in ACCOMPLISH - thus we suspect a benefit beyond the BP lowering effect. Possibly, chlorthalidone is better than HCTZ. Thus, in the USA, the Joint National Committee 8 is considering removing HCTZ from their first line recommendation and favoring chlorthalidone instead. You may also claim that ACCOMPLISH may need confirmation before making too strong a recommendation - we usually base our guidelines on at least two studies showing a principle. I still think, though, ACEI/HCTZ and ARB/HCTZ are excellent drug combinations. Think of LIFE, in which we, for first time in history of hypertension research, were able to show superiority for one combination over another. (ARB/HCTZ was better than HCTZ/beta-blocker.)

版面编辑:沈会会  责任编辑:张衡


氨氯地平ACEIARB

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530